The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis

  • Lee, Ji-Hye (Department of Pathology, Soonchunhyang University College of Medicine) ;
  • Oh, Mee-Hye (Department of Pathology, Soonchunhyang University College of Medicine) ;
  • Park, Jae-Seok (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Na, Gyoung-Jae (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Gil, Hye-Wook (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Yang, Jong-Oh (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Lee, Eun-Young (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Hong, Sae-Yong (Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • Received : 2012.10.09
  • Accepted : 2013.05.23
  • Published : 2014.03.01
⟨ Previous Next ⟩

Abstract

Background/Aims: The purpose of this study was to investigate the expression of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor (PAI)-1 on podocytes in immunoglobulin A (IgA) glomerulonephritis (GN). Methods: Renal biopsy specimens from 52 IgA GN patients were deparaffinized and subjected to immunohistochemical staining for uPA, PAI-1, and uPAR. The biopsies were classified into three groups according to the expression of uPA and uPAR on podocytes: uPA, uPAR, and a negative group. The prevalences of the variables of the Oxford classification for IgA GN were compared among the groups. Results: On podocytes, uPA was positive in 11 cases and uPAR was positive in 38 cases; by contrast, PAI-1 was negative in all cases. Expression of both uPA and uPAR on podocytes was less frequently accompanied by tubulointerstitial fibrosis. Conclusions: Our results suggest a possible protective effect of podocyte uPA/uPAR expression against interstitial fibrosis.

Keywords

References

  1. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007;97:336-342. https://doi.org/10.1160/TH06-11-0669
  2. Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012;157:291-298. https://doi.org/10.1111/j.1365-2141.2012.09074.x
  3. Chen W, Jin WQ, Chen LF, Williams T, Zhu WL, Fang Q. Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis. Int J Cardiol 2012;161:103-110. https://doi.org/10.1016/j.ijcard.2011.12.094
  4. Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost 2010;104:875-885. https://doi.org/10.1160/TH10-01-0017
  5. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006;5:1760-1771. https://doi.org/10.4161/cc.5.16.2994
  6. Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009;5:463-468.
  7. Tkachuk N, Kiyan J, Tkachuk S, et al. Urokinase induces survival or pro-apoptotic signals in human mesangial cells depending on the apoptotic stimulus. Biochem J 2008;415:265-273. https://doi.org/10.1042/BJ20071652
  8. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inf lammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546-1557. https://doi.org/10.1038/ki.1995.218
  9. Lorenzen J, Shah R, Biser A, et al. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol 2008;19:884-890. https://doi.org/10.1681/ASN.2007040486
  10. Zhang G, Kim H, Cai X, et al. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 2003;14:1254-1271. https://doi.org/10.1097/01.ASN.0000064292.37793.FB
  11. Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, Eddy AA. Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol 2007;293:F12-F19. https://doi.org/10.1152/ajprenal.00380.2006
  12. Huang Y, Noble N. An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis. Kidney Int 2005;67:2502-2503. https://doi.org/10.1111/j.1523-1755.2005.00368.x
  13. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546-556. https://doi.org/10.1038/ki.2009.168
  14. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008;87:617-629. https://doi.org/10.1016/j.ejcb.2008.02.003
  15. Alfano D, Franco P, Vocca I, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005;93:205-211.
  16. Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci 1992;667:13-31. https://doi.org/10.1111/j.1749-6632.1992.tb51591.x
  17. Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004;91:425-437.
  18. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49. https://doi.org/10.2174/1381612043453559
  19. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-1197.
  20. Behrendt N, List K, Andreasen PA, Dano K. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J 2003;371(Pt 2):277-287. https://doi.org/10.1042/BJ20021508
  21. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991;87:962-970. https://doi.org/10.1172/JCI115104
  22. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17:952-960. https://doi.org/10.1038/nm.2411
  23. Hong SY, Yang DH, Kim PN. Urokinase concentration in the renal artery and vein. Nephron 1992;61:176-180. https://doi.org/10.1159/000186867

Cited by

  1. Urokinase-type plasminogen activator receptor in IgA nephropathy vol.29, pp.2, 2014, https://doi.org/10.3904/kjim.2014.29.2.166
  2. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy vol.10, pp.7, 2014, https://doi.org/10.1371/journal.pone.0132869
  3. Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity vol.7, pp.23, 2014, https://doi.org/10.18632/oncotarget.9033